Healthcare
Canopy Growth Corporation(CGC)
Live Price
Offline$1.00
-0.99% today
1Y Change
-22.11%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $270.00M
- Revenue Growth
- -9.5%
- EPS Growth
- +14.5%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Canopy Growth Corporation (CGC) is a Healthcare stock with a market cap of $270.00M and listed on NASDAQ. The stock last traded around $1.00 and down 22.1% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -9.5%, EPS growth of +14.5%, a dividend yield of 0.0%. What stands out right now is revenue -9.5%, EPS +14.5%, free cash flow +38.1% with operating margin -25.5% and ROIC -6.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CGC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-9.5% vs +7.6% peer median
Operating Margin
Below sector median
-25.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -9.5% and EPS is at +14.5%, with operating margin around -25.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 29, 2026 | โ | -0.9% | -5.5% | โ |
2026 Feb 6, 2026 | -233.3% | -0.9% | -1.8% | -2.7% |
2025 Nov 7, 2025 | +90.9% | +8.5% | -8.5% | -6.8% |
Benchmark Edge
CGC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CGC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CGC Max Drawdown
-55.36%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CGC and SPY.
Company Overview
Canopy Growth Corporation
NASDAQ
Canopy Growth Corporation is a leading cannabis producer and distributor engaged in the production, distribution, and sale of cannabis, hemp, and cannabis-related products across multiple markets including Canada, Germany, and Australia. The company operates through four primary business segments: Canada Cannabis, International Markets Cannabis, Storz & Bickel, and This Works. Canopy Growth's product portfolio spans dried flower and pre-rolled joints, cannabis extracts and concentrates including softgel capsules, cannabis edibles such as gummies, vapes, and oils, as well as beverages and concentrates. The company serves both adult-use and medical cannabis markets, with particular strength in Canadian medical cannabis. Storz & Bickel, a subsidiary, specializes in manufacturing high-end, medically certified cannabis vaporizers. Headquartered in Smith Falls, Ontario, and founded in 2009, Canopy Growth distributes its products through online channels, retail outlets, and partnerships with various resellers and provincial retailers, positioning itself as a significant player in the evolving global cannabis industry.
- Leadership
- Mr. Luc Mongeau
- Employees
- 960
- Street Address
- 1 Hershey Drive
- Mailing
- Smiths Falls, ON, K7A 0A8
- Region
- Smiths Falls, ON, Canada
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.0
- Price/Book
- 0.7
Growth
- Revenue
- -9.5%
- EPS
- +14.5%
- Free Cash Flow
- +38.1%
Profitability
- Gross Margin
- 24.1%
- Operating Margin
- -25.5%
- Net Margin
- -117.3%
- ROE
- -52.9%
- ROIC
- -6.9%
Balance Sheet
- Debt/Equity
- 0.36
- Current Ratio
- 5.34
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.